Skip to search formSkip to main contentSkip to account menu

ledipasvir / sofosbuvir Oral Tablet [Harvoni]

National Institutes of Health

Related topics

Related topics

3 relations
HarvoniOral Tablet

Narrower (1)

ledipasvir 90 MG / sofosbuvir 400 MG Oral Tablet [Harvoni]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Libertad de acción para producir medicamentos antivirales de acción directa antihepatitis C en Cuba
Introduccion : Los medicamentos antihepatitis C recomendados son combinaciones de al menos dos ingredientes farmaceuticos activos… 
2019
2019
The Clinical Development of Ledipasvir/Sofosbuvir (LDV/SOF, Harvoni®)
The fixed-dose combination tablet of ledipasvir (LDV), an HCV NS5A inhibitor, and sofosbuvir (SOF), an HCV nucleotide analog NS5B… 
2019
2019
The Discovery of Ledipasvir (GS-5885): The Potent Once-Daily Oral HCV NS5A Inhibitor in the Single-Tablet Regimen Harvoni®
The advent of direct-acting antiviral agents (DAAs) has revolutionized the treatment and cure of chronic hepatitis C virus (HCV… 
2017
2017
Sustained Viral Response after Treatment with Ledipasvir/Sofosbuvir (Harvoni®) in a Patient with Hepatitis C Following Intestine and Renal Transplantation
Review
2016
Review
2016
Current and Emerging Therapeutic Regimens for Patients with Chronic Hepatitis C Infection
With 5.2 million people living with Hepatitis C, it is the most common blood-borne infection in the United States. Untreated… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)